使用基因載體作為治療工具的挑戰在於是否能控制在特定組織
局部釋放載體，一個可能的解決方法是植入帶有病毒的組織工程支
架，以達到局部基因傳遞的效果。在這篇研究中我們先將第二型重組
類腺病毒與肝素化小腸黏膜結合，再將細胞加到帶有病毒的小腸黏膜
上，細胞貼附生長後達到基因轉導的效果。肝素是第二型重組類腺病
毒的接受器，肝素化小腸黏膜的製備是利用交聯劑EDC 和NHS 將肝
素與小腸黏膜作交聯，肝素化後的小腸黏膜可用來吸附第二型重組類
腺病毒。從報導基因EGFP 和β-galactosidase 的表現顯示出肝素化小腸
黏膜所吸附的病毒具有活性，可以在培養細胞時達到基因傳遞的效
果。我們的研究顯示出經過化學修飾後的組織，也就是肝素化小腸黏
膜，具有吸附第二型重組類腺病毒和基因轉導的效果，所以肝素化小
腸黏膜可以做為局部基因傳遞一個很好的工具。

A major challenge in the use of gene transfer vectors as therapeutic tools is
controlling vector administration at a desired tissue site. One potential solution is
implanting tissue-engineering constructs loaded with gene transfer vectors such as
viruses for localized transgene delivery. In this work, we conjugated recombinant
adeno-associated virus serotype 2 (rAAV2) to a heparinized small intestinal
submucosa (H-SIS) matrix, which resulted in vector transduction upon cellular
adhesion. H-SIS was prepared by incorporating heparin, the rAAV2 receptor, into SIS
through N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide (EDC) and
N-hydroxysuccinimide (NHS) mediated crosslinking. Incorporated heparin adsorbed
rAAV2 onto the H-SIS matrix for conjugation. Using green fluorescent protein and
□-galactosidase as reporters, we showed that conjugated rAAV2 was active and
capable of mediating transgene delivery in cell culture. Our work provides a unique,
modified tissue substrate H-SIS for rAAV2 binding and transduction, which can be a
useful tool in developing localized gene transfer.

1. Mizuguchi, H. and T. Hayakawa, Targeted adenovirus vectors. Hum Gene Ther, 2004. 15(11): p. 1034-44.
2. Muzyczka, N. and K.H. Warrington, Jr., Custom adeno-associated virus capsids: the next generation of recombinant vectors with novel tropism. Hum Gene Ther, 2005. 16(4): p. 408-16.
3. Ponnazhagan, S., et al., Conjugate-based targeting of recombinant adeno-associated virus type 2 vectors by using avidin-linked ligands. J Virol, 2002. 76(24): p. 12900-7.
4. Yun, Y.H., et al., Hyaluronan microspheres for sustained gene delivery and site-specific targeting. Biomaterials, 2004. 25(1): p. 147-57.
5. Raty, J.K., et al., Enhanced gene delivery by avidin-displaying baculovirus. Mol Ther, 2004. 9(2): p. 282-91.
6. Pandori, M., D. Hobson, and T. Sano, Adenovirus-microbead conjugates possess enhanced infectivity: a new strategy for localized gene delivery. Virology, 2002. 299(2): p. 204-12.
7. Scherer, F., et al., Magnetofection: enhancing and targeting gene delivery by magnetic force in vitro and in vivo. Gene Ther, 2002. 9(2): p. 102-9.
8. Segura, T., P.H. Chung, and L.D. Shea, DNA delivery from hyaluronic acid-collagen hydrogels via a substrate-mediated approach. Biomaterials, 2005. 26(13): p. 1575-84.
9. Guo, T., et al., Porous chitosan-gelatin scaffold containing plasmid DNA encoding transforming growth factor-beta1 for chondrocytes proliferation. Biomaterials, 2006. 27(7): p. 1095-103.
10. Huang, Y.C., et al., Long-term in vivo gene expression via delivery of PEI-DNA condensates from porous polymer scaffolds. Hum Gene Ther, 2005. 16(5): p. 609-17.
11. De Laporte, L., J. Cruz Rea, and L.D. Shea, Design of modular non-viral gene therapy vectors. Biomaterials, 2006. 27(7): p. 947-54.
12. Stachelek, S.J., et al., Localized gene delivery using antibody tethered adenovirus from polyurethane heart valve cusps and intra-aortic implants. Gene Ther, 2004. 11(1): p. 15-24.
13. Levy, R.J., et al., Localized adenovirus gene delivery using antiviral IgG complexation. Gene Ther, 2001. 8(9): p. 659-67.
14. Gu, D.L., et al., Adenovirus encoding human platelet-derived growth factor-B delivered in collagen exhibits safety, biodistribution, and immunogenicity profiles favorable for clinical use. Mol Ther, 2004. 9(5): p. 699-711.
15. Mima, H., et al., Biocompatible polymer enhances the in vitro and in vivo transfection efficiency of HVJ envelope vector. J Gene Med, 2005. 7(7): p. 888-97.
16. Bellocq, N.C., et al., Synthetic biocompatible cyclodextrin-based constructs for local gene delivery to improve cutaneous wound healing. Bioconjug Chem, 2004. 15(6): p. 1201-11.
17. Koefoed, M., et al., Biological effects of rAAV-caAlk2 coating on structural allograft healing. Mol Ther, 2005. 12(2): p. 212-8.
18. Ito, H., et al., Remodeling of cortical bone allografts mediated by adherent rAAV-RANKL and VEGF gene therapy. Nat Med, 2005. 11(3): p. 291-7.
19. Moss, R.B., et al., Repeated adeno-associated virus serotype 2 aerosol-mediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: a multicenter, double-blind, placebo-controlled trial. Chest, 2004. 125(2): p. 509-21.
20. Manno, C.S., et al., Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med, 2006. 12(3): p. 342-7.
21. Marshall, E., Gene therapy death prompts review of adenovirus vector. Science, 1999. 286(5448): p. 2244-5.
22. Hacein-Bey-Abina, S., et al., A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med, 2003. 348(3): p. 255-6.
23. RO, S., Adeno-associated virus-mediated gene delivery. J Gene Med, 1999. 1(3): p. 166-75.
24. Summerford, C. and R.J. Samulski, Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. Journal of Virology, 1998. 72(2): p. 1438-1445.
25. Auricchio, A., et al., Isolation of highly infectious and pure adeno-associated virus type 2 vectors with a single-step gravity-flow column. Human Gene Therapy, 2001. 12(1): p. 71-76.
26. Brown-Etris, M., W.D. Cutshall, and M.C. Hiles, A new biomaterial derived from small intestine submucosa and developed into a wound matrix device. Wounds-a Compendium of Clinical Research and Practice, 2002. 14(4): p. 150-166.
27. Demling, R.H., et al., Small intestinal submucosa wound matrix and full-thickness venous ulcers: Preliminary results. Wounds-a Compendium of Clinical Research and Practice, 2004. 16(1): p. 18-22.
28. Mostow, E.N., et al., Effectiveness of an extracellular matrix graft (OASIS Wound Matrix) in the treatment of chronic leg ulcers: a randomized clinical trial. J Vasc Surg, 2005. 41(5): p. 837-43.
29. Keuren, J.F., et al., Covalently-bound heparin makes collagen thromboresistant. Arterioscler Thromb Vasc Biol, 2004. 24(3): p. 613-7.
30. Wissink, M.J., et al., Improved endothelialization of vascular grafts by local release of growth factor from heparinized collagen matrices. J Control Release, 2000. 64(1-3): p. 103-14.
31. Wissink, M.J., et al., Immobilization of heparin to EDC/NHS-crosslinked collagen. Characterization and in vitro evaluation. Biomaterials, 2001. 22(2): p. 151-63.
32. Wissink, M.J., et al., Binding and release of basic fibroblast growth factor from heparinized collagen matrices. Biomaterials, 2001. 22(16): p. 2291-9.
33. Yao, C., et al., Modification of collagen matrices for enhancing angiogenesis. Cells Tissues Organs, 2004. 178(4): p. 189-96.
34. Yao, C., et al., The impact of proteinase-induced matrix degradation on the release of VEGF from heparinized collagen matrices. Biomaterials, 2006. 27(8): p. 1608-16.
35. assay, P.f.t.b., The impact of proteinase-induced matrix degradation on the release of VEGF from heparinized collagen matrices. Biomaterials. 27(8): p. 1608-16.
36. Berridge, M.V. and A.S. Tan, Characterization of the cellular reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT): subcellular localization, substrate dependence, and involvement of mitochondrial electron transport in MTT reduction. Arch Biochem Biophys, 1993. 303(2): p. 474-82.
37. Qing, K., et al., Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2. Nat Med, 1999. 5(1): p. 71-7.
38. Kashiwakura, Y., et al., Hepatocyte growth factor receptor is a coreceptor for adeno-associated virus type 2 infection. J Virol, 2005. 79(1): p. 609-14.
39. Hurst, R.E. and R.B. Bonner, Mapping of the distribution of significant proteins and proteoglycans in small intestinal submucosa by fluorescence microscopy. J Biomater Sci Polym Ed, 2001. 12(11): p. 1267-79.
40. Summerford, C., J.S. Bartlett, and R.J. Samulski, AlphaVbeta5 integrin: a co-receptor for adeno-associated virus type 2 infection. Nat Med, 1999. 5(1): p. 78-82.
41. Hodde, J., Naturally occurring scaffolds for soft tissue repair and regeneration. Tissue Eng, 2002. 8(2): p. 295-308.
42. Kini, S., et al., A biodegradeable membrane from porcine intestinal submucosa to reinforce the gastrojejunostomy in laparoscopic Roux-en-Y gastric bypass: preliminary report. Obes Surg, 2001. 11(4): p. 469-73.
43. Schultz, D.J., et al., Porcine small intestine submucosa as a treatment for enterocutaneous fistulas. J Am Coll Surg, 2002. 194(4): p. 541-3.
44. Ueno, T., et al., Clinical application of porcine small intestinal submucosa in the management of infected or potentially contaminated abdominal defects. J Gastrointest Surg, 2004. 8(1): p. 109-12.
45. Colvert, J.R., 3rd, et al., The use of small intestinal submucosa as an off-the-shelf urethral sling material for pediatric urinary incontinence. J Urol, 2002. 168(4 Pt 2): p. 1872-5; discussion 1875-6.
46. Baum, C., et al., Mutagenesis and oncogenesis by chromosomal insertion of gene transfer vectors. Hum Gene Ther, 2006. 17(3): p. 253-63.
47. Nakai, H., et al., AAV serotype 2 vectors preferentially integrate into active genes in mice. Nat Genet, 2003. 34(3): p. 297-302.
48. Compton, T., D.M. Nowlin, and N.R. Cooper, Initiation of human cytomegalovirus infection requires initial interaction with cell surface heparan sulfate. Virology, 1993. 193(2): p. 834-41.
49. Pajusola, K., et al., Cell-type-specific characteristics modulate the transduction efficiency of adeno-associated virus type 2 and restrain infection of endothelial cells. Journal of Virology, 2002. 76(22): p. 11530-11540.
50. Burova, E. and E. Ioffe, Chromatographic purification of recombinant adenoviral and adeno-associated viral vectors: methods and implications. Gene Ther, 2005. 12 Suppl 1: p. S5-17.
51. Duffy, A.M., et al., Purification of adenovirus and adeno-associated virus: comparison of novel membrane-based technology to conventional techniques. Gene Ther, 2005. 12 Suppl 1: p. S62-72.
52. Brument, N., et al., A versatile and scalable two-step ion-exchange chromatography process for the purification of recombinant adeno-associated virus serotypes-2 and -5. Mol Ther, 2002. 6(5): p. 678-86.
53. Tsai, C.C., et al., Effects of heparin immobilization on the surface characteristics of a biological tissue fixed with a naturally occurring crosslinking agent (genipin): an in vitro study. Biomaterials, 2001. 22(6): p. 523-533.
54. Eming, S.A., H. Smola, and T. Krieg, Treatment of chronic wounds: State of the art and future concepts. Cells Tissues Organs, 2002. 172(2): p. 105-117.
55. Deodato, B., et al., Recombinant AAV vector encoding human VEGF165 enhances wound healing. Gene Therapy, 2002. 9(12): p. 777-785.
56. Beck, S.E., et al., Repeated delivery of adeno-associated virus vectors to the rabbit airway. Journal of Virology, 1999. 73(11): p. 9446-9455.
57. Okada, Y., et al., An investigation of adverse effects caused by the injection of high-dose TNF alpha-expressing adenovirus vector into established murine melanoma. Gene Therapy, 2003. 10(8): p. 700-705.
58. Okada, Y., et al., Optimization of antitumor efficacy and safety of in vivo cytokine gene therapy using RGD fiber-mutant adenovirus vector for preexisting murine melanoma. Biochimica Et Biophysica Acta-General Subjects, 2004. 1670(3): p. 172-180.
59. Bell, P., et al., No evidence for tumorigenesis of AAV vectors in a large-scale study in mice. Molecular Therapy, 2005. 12(2): p. 299-306.
60. Bennett, J., Immune response following intraocular delivery of recombinant viral vectors. Gene Therapy, 2003. 10(11): p. 977-982.
61. Bueler, H., Adeno associated viral vectors for gene transfer and gene therapy. Biological Chemistry, 1999. 380(6): p. 613-622.
62. Tang, S.C., A. Sambanis, and E. Sibley, Proteasome modulating agents induce rAAV2-mediated transgene expression in human intestinal epithelial cells. Biochemical and Biophysical Research Communications, 2005. 331(4): p. 1392-1400.
63. Landazuri, N. and J.M. Le Doux, Complexation with chondroitin sulfate C and polybrene rapidly purifies retrovirus from inhibitors of transduction and substantially enhances gene transfer. Biotechnology and Bioengineering, 2006. 93(1): p. 146-158.
64. Veldwijk, M. R.; Topaly, J.; Laufs, S.; Henegge, U. R.; Wenz, F.; Zeller, W. J.; Fruehauf, S., Development and optimization of a real-time quantitative PCR-Based method for the titration of AAV-2 vector stocks (vol 6, pg 272, 2002). Molecular Therapy 2002, 6, (3), 429-429.